| SEC Info ||Home||Search||My Interests||Help||Sign In||Please Sign In|
As Of Filer Filing For/On/As Docs:Size Issuer Agent 8/28/12 Ziopharm Oncology Inc 10-Q/A 6/30/12 50:3.1M Vintage Filings/FA
Document/Exhibit Description Pages Size 1: 10-Q/A Amendment to Quarterly Report HTML 29K 2: EX-31.1 Certification per Sarbanes-Oxley Act (Section 302) HTML 20K 3: EX-31.2 Certification per Sarbanes-Oxley Act (Section 302) HTML 20K 4: EX-32.1 Certification per Sarbanes-Oxley Act (Section 906) HTML 18K 49: XML XBRL XML File -- Filing Summary XML 78K 32: R1 Document and Entity Information HTML 37K 23: R2 Balance Sheets HTML 124K 30: R3 Balance Sheets (Parenthetical) HTML 42K 34: R4 Statements Of Operations HTML 74K 46: R5 Statement Of Stockholders' Equity HTML 74K 24: R6 Statement Of Stockholders' Equity (Parenthetical) HTML 18K 29: R7 Statements of Cash Flows HTML 154K 21: R8 Business HTML 25K 15: R9 Summary of Significant Accounting Policies HTML 21K 47: R10 Collaborations and Alliances HTML 21K 36: R11 Fair Value Measurements HTML 36K 35: R12 Net Loss per Share HTML 23K 40: R13 Related Party Transactions HTML 23K 41: R14 Commitments and Contingencies HTML 51K 39: R15 Warrants HTML 46K 42: R16 Common Stock HTML 19K 31: R17 Stock-Based Compensation HTML 38K 33: R18 Fair Value Measurements (Tables) HTML 24K 38: R19 Net Loss per Share (Tables) HTML 21K 50: R20 Warrants (Tables) HTML 36K 44: R21 Stock-Based Compensation (Tables) HTML 42K 26: R22 Business - Additional Information (Detail) HTML 25K 37: R23 Collaborations and Alliances - Additional HTML 24K Information (Detail) 28: R24 Assets and Liabilities Measured at Fair Value on HTML 26K Recurring Basis (Detail) 13: R25 Potential Dilutive Shares Excluded from HTML 27K Computation of Diluted Net Loss Per Share (Detail) 45: R26 Related Party Transactions - Additional HTML 29K Information (Detail) 48: R27 Commitments and Contingencies - Additional HTML 122K Information (Detail) 18: R28 Number of Warrants Outstanding (Detail) HTML 21K 17: R29 Warrants - Additional Information (Detail) HTML 74K 19: R30 Assumptions Used In Binomial Valuation Model and HTML 25K Black-Scholes Valuation Model (Detail) 20: R31 Warrant Exercise (Detail) HTML 31K 22: R32 Common Stock - Additional Information (Detail) HTML 35K 11: R33 Stock-Based Compensation Expense on All Employee HTML 23K and Non-Employee Awards (Detail) 43: R34 Stock-Based Compensation - Additional Information HTML 32K (Detail) 25: R35 Fair Value of Stock Options Assumptions Using HTML 35K Black-Scholes Option Valuation Model (Detail) 27: R36 Stock Option Activity Under Stock Option Plan HTML 86K (Detail) 14: R37 Summary of Unvested Restricted Stock (Detail) HTML 48K 16: EXCEL XBRL IDEA Workbook -- Financial Report XLS 392K 5: EX-101.INS XBRL Instance -- ziop-20120630 XML 724K 7: EX-101.CAL XBRL Calculations -- ziop-20120630_cal XML 104K 8: EX-101.DEF XBRL Definitions -- ziop-20120630_def XML 610K 9: EX-101.LAB XBRL Labels -- ziop-20120630_lab XML 902K 10: EX-101.PRE XBRL Presentations -- ziop-20120630_pre XML 686K 6: EX-101.SCH XBRL Schema -- ziop-20120630 XSD 143K 12: ZIP XBRL Zipped Folder -- 0001144204-12-048414-xbrl ZIP 101K
Related Party Transactions
|106 Months Ended|
|Related Party Transactions||
6. Related Party Transactions
On January 6, 2011, the Company entered into an Exclusive Channel Partner Agreement (the “Channel Agreement”) with Intrexon Corporation (see Note 7 for additional disclosure relating to the Channel Agreement). During the six months ended June 30, 2012, the Company paid Intrexon approximately $10.7 million, of which $2.5 million was for services already incurred and the remaining $8.2 million expected to be incurred within a year. This amount has been included as part of prepaid expenses and other current assets on the accompanying balance sheet as of June 30, 2012. The Company does not owe any amounts to Intrexon that have not already been accrued for as of June 30, 2012.
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
Reference 1: http://www.xbrl.org/2003/role/presentationRef
|This 10-Q/A Filing||Date||Other Filings|
|1/25/12||8-K, SC 13D/A|
|For The Period Ended||6/30/12||10-Q|
|Filed On / Filed As Of||8/28/12|
|Top||List All Filings|